Home > Insider Trading > Filing (0001072613-13-000281)

Filing Details

Accession Number:: 0001072613-13-000281
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2013-06-13 17:00:39
Reporting Period:: 2013-06-11

Filing Date:: 2013-06-13
Accepted Time:: 2013-06-13 17:00:39
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1526119	Verastem Inc.	VSTM	Pharmaceutical Preparations (2834)	273269467

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1384619	Chp Iii Lp	C/O Cardinal Partners 230 Nassau Street Princeton NJ 08542		No	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2013-06-11	25,000	$9.22	2,305,950	No	4	P	Direct
Common Stock	Acquisiton	2013-06-12	23,171	$9.60	2,329,121	No	4	P	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Direct
No	4	P	Direct

Footnotes

Represents a weighted-average price. These shares were purchased in multiple transactions at prices ranging from $9.15 to $9.51, inclusive. For all transactions reported in this Form 4 utilizing a weighted-average price, the reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares purchased at each price within the range.
CHP III Management, L.L.C.(the "GP") is the sole General Partner of CHP III, L.P. John K. Clarke, Brandon H. Hull, Charles G. Hadley and John J. Park (collectively, the "Managing Members") are Managing Members of the GP, and, as such, may be deemed to have shared voting and dispositive power with respect to the issuer's securities held of CHP III, L.P. (the "CHP III Shares"). Each of the GP and the Managing Members disclaims beneficial ownership of the CHP III Shares, except to the extent of their respective pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of the shares for purposes of Section 16 or for any other purpose.
Represents a weighted-average price. These shares were purchased in multiple transactions at prices ranging from $9.36 to $9.75, inclusive. For all transactions reported in this Form 4 utilizing a weighted-average price, the reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares purchased at each price within the range.